# Summary of minutes of EUCAST Steering Committee Meeting

**Madrid, Spain, 8-9 February 2016**

## Attending

<table>
<thead>
<tr>
<th>Name</th>
<th>Role</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr Derek F.J. Brown</td>
<td>DB</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Dr Rafael Cantón</td>
<td>RC</td>
<td>Spain</td>
</tr>
<tr>
<td>Prof Gerard Lina</td>
<td>GL</td>
<td>France</td>
</tr>
<tr>
<td>Dr Christian Giske</td>
<td>CG</td>
<td>Sweden</td>
</tr>
<tr>
<td>Prof Gunnar Kahlmeter</td>
<td>GK</td>
<td>Sweden</td>
</tr>
<tr>
<td>Dr P. Christoffer Lindemann</td>
<td>CL</td>
<td>Norway</td>
</tr>
<tr>
<td>Prof Alasdair P. MacGowan</td>
<td>AM</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Prof Johan W. Mouton</td>
<td>JM</td>
<td>The Netherlands</td>
</tr>
<tr>
<td>Prof Sören Gatermann</td>
<td>SG</td>
<td>Germany</td>
</tr>
</tbody>
</table>

## Apologies

- Dr Iztok Štrumbelj (EUCAST General Committee, Slovenia)
- Prof Jan Verhagen (EUCAST General Committee, Belgium)

## Present for item 19

- Eumedica representatives

## 1 Chairman’s welcome

## 2 Minutes of meeting of 8-9 November 2015

- With minor corrections the minutes were accepted as a correct record.

## 3 Matters arising from minutes of 8-9 November (items not covered by agenda)

- None.

## 4 New agents

- Ceftazidime-avibactam breakpoints were discussed.

## 5 EUCAST rationale documents

- Several documents are being developed or updated.

## 6 Subcommittees

- Antifungal susceptibility testing (AFST): The place of molecular tests for resistance genes in place of MIC breakpoints was considered to be supplementary rather than a replacement.

- Whole genome sequencing (WGS): A report is expected in time for ECCMID 2016.

- VetCAST: Issues in breakpoint setting have been discussed between the Steering Committee and the Subcommittee.

- MIC distributions and ECOFFs: The issues associated with assessment of the acceptability of MIC distributions for inclusion in aggregated distributions on the MIC distribution website and approaches to setting ECOFFs are being reviewed.

- Antimycobacterial susceptibility testing: The subcommittee has now been established.

## 7 Breakpoint issues

- Breakpoint tables version 6.0 have been released on the website.

- A guidance document is being produced on the implications of splitting wild type and resistant populations in breakpoint setting.

- Zone diameter breakpoints for high level streptomycin resistance in *Enterococcus* spp have been set.

- Flow charts for disk diffusion screen tests for susceptibility to β-lactam agents in *S. pneumoniae* and *H. influenzae* are being developed.

- Discrepancies when testing *H. influenzae* against β-lactam agents are largely associated with isolates that have PBP mutations. Options for improving test reliability are being investigated.

- A guidance note on susceptibility testing of *N. gonorrhoeae* is to be drafted.
Multiple comments in response to the consultation on the revised intermediate category definition were reviewed. In view of the comments it was agreed that it would not be acceptable to remove the concept of a buffer zone at present.

There will be a wide consultation on a proposal to reduce colistin breakpoints for *Pseudomonas* spp. to $S \leq 2$, $R > 2$ mg/L.

Review of carbapenem and fluoroquinolone breakpoints is continuing.

Following wide consultation, revision of the intrinsic resistance and unusual resistance tables is close to completion.

A guidance document on use of daptomycin to treat serious enterococcal infections is about to be released.

Revision of tigecycline breakpoints for Enterobacteriaceae is being considered.

Nitrooxine breakpoints have been finalised and will be released.

**Organisms without EUCAST breakpoints** MIC and zone diameter data have been prepared for *Aerococcus* spp and *Kingella kingae*. Work on *Aeromonas* spp. and *Plesiomonas shigelloides* has been started.

**EUCAST methods**
The EUCAST Development Laboratory is involved in a wide range of projects related to development of EUCAST breakpoints and methods.

A series of videos on the disk diffusion method is being prepared for the WHO.

The problem of variable use of abbreviations for antimicrobial agents on disks and other devices was highlighted and manufacturers will be approached with aim of standardisation.

**Implementation of EUCAST breakpoints** No new information was presented.

**EUCAST websites** A separate section with all open consultations and responses is being prepared.

**Publications and presentations** No new information was presented.

**NACs** No new information was presented.

**EUCAST documents**
A revised version of SOP 4, Committees and subcommittees, was approved and will be released.

EUCAST statutes are being revised to reflect changes in committee structures.

**ESCMID** The final programme for the 2016 Postgraduate Educational Course on susceptibility testing was approved.

**EMA** Revision of the EMA-EUCAST SOP is still being discussed.

**ECDC** The first specific contract for the current framework contract has been signed.

**CLSI** No new information.

**Temocillin breakpoints** Information relevant to breakpoints was discussed with Eumedica.

**Any other business**
From the end of 2016, John Turnidge from Melbourne, Australia, will take over as EUCAST Scientific Secretary. From ECCMID in April 2016, the new General Committee representatives on the Steering Committee will be Deniz Gür (Turkey) and Arjana Tambic Andrasevic (Croatia).
Next meetings

12-13 April 2016, Amsterdam, The Netherlands
4-5 July 2016, Stockholm, Sweden
19-20 September 2016, Bochum, Germany (before PGEC)
21-22 November 2016, Windsor, London
6-7 February 2017, Rotterdam, The Netherlands
25-26 April 2017, Vienna, Austria (immediately following ECCMID)
10-11 July 2017, Stockholm, Sweden

Ratified summary of minutes of meeting 8-9 February 2016. Prepared by DB, RC, CG and GK